immunocore holdings - IMCR

IMCR

Close Chg Chg %
36.19 0.38 1.05%

Closed Market

36.57

+0.38 (1.05%)

Volume: 120.65K

Last Updated:

Dec 24, 2025, 1:00 PM EDT

Company Overview: immunocore holdings - IMCR

IMCR Key Data

Open

$36.40

Day Range

35.51 - 37.25

52 Week Range

23.15 - 40.71

Market Cap

$1.83B

Shares Outstanding

50.47M

Public Float

50.08M

Beta

0.77

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.58

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

298.55K

 

IMCR Performance

1 Week
 
1.56%
 
1 Month
 
-7.42%
 
3 Months
 
7.50%
 
1 Year
 
25.33%
 
5 Years
 
N/A
 

IMCR Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 17
Full Ratings ➔

About immunocore holdings - IMCR

Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. Its lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.

IMCR At a Glance

Immunocore Holdings Plc
92 Park Drive
Abingdon, Oxfordshire OX14 4RY
Phone 44-1235-438600 Revenue 310.33M
Industry Biotechnology Net Income -51,108,496.83
Sector Health Technology 2024 Sales Growth 23.937%
Fiscal Year-end 12 / 2025 Employees 493
View SEC Filings

IMCR Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 4.752
Price to Book Ratio 4.118
Price to Cash Flow Ratio 56.56
Enterprise Value to EBITDA -16.40
Enterprise Value to Sales 3.503
Total Debt to Enterprise Value 0.398

IMCR Efficiency

Revenue/Employee 629,477.747
Income Per Employee -103,668.351
Receivables Turnover 3.735
Total Asset Turnover 0.386

IMCR Liquidity

Current Ratio 4.382
Quick Ratio 4.357
Cash Ratio 3.866

IMCR Profitability

Gross Margin 97.764
Operating Margin -22.715
Pretax Margin -17.065
Net Margin -16.469
Return on Assets -6.363
Return on Equity -14.011
Return on Total Capital -6.441
Return on Invested Capital -8.221

IMCR Capital Structure

Total Debt to Total Equity 119.962
Total Debt to Total Capital 54.538
Total Debt to Total Assets 42.865
Long-Term Debt to Equity 119.533
Long-Term Debt to Total Capital 54.343
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Immunocore Holdings - IMCR

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
36.47M 177.05M 250.39M 310.33M
Sales Growth
-5.55% +385.43% +41.42% +23.94%
Cost of Goods Sold (COGS) incl D&A
- 8.11M 5.16M 6.94M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
9.64M 7.55M 4.12M 4.21M
Depreciation
9.64M 7.55M 4.12M 4.21M
Amortization of Intangibles
- - - -
-
COGS Growth
- - -36.42% +34.54%
-
Gross Income
- 168.94M 245.24M 303.39M
Gross Income Growth
- - +45.16% +23.71%
-
Gross Profit Margin
- +95.42% +97.94% +97.76%
2021 2022 2023 2024 5-year trend
SG&A Expense
213.51M 232.89M 305.12M 373.89M
Research & Development
101.20M 110.06M 164.18M 222.24M
Other SG&A
112.31M 122.83M 140.94M 151.64M
SGA Growth
+49.57% +9.08% +31.01% +22.54%
Other Operating Expense
- - - -
-
Unusual Expense
- - - (10.70M)
-
EBIT after Unusual Expense
(186.68M) (63.95M) (59.88M) (59.79M)
Non Operating Income/Expense
367.21K 17.11M 3.93M 21.78M
Non-Operating Interest Income
64.64K 3.89M 18.06M 25.63M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
7.99M 7.76M 5.17M 14.95M
Interest Expense Growth
+100.53% -2.95% -33.32% +188.95%
Gross Interest Expense
7.99M 7.76M 5.17M 14.95M
Interest Capitalized
- - - -
-
Pretax Income
(194.31M) (54.60M) (61.13M) (52.96M)
Pretax Income Growth
-73.00% +71.90% -11.95% +13.36%
Pretax Margin
-532.75% -30.84% -24.41% -17.07%
Income Tax
(13.43M) (3.82M) (5.62M) (1.85M)
Income Tax - Current - Domestic
(12.31M) (2.70M) (215.83K) 1.47M
Income Tax - Current - Foreign
- 964.48K 456.76K 500.21K
Income Tax - Deferred - Domestic
(623.01K) (1.87M) (5.90M) (3.82M)
Income Tax - Deferred - Foreign
- - - 30.12K
-
Income Tax Credits
- - 492.36K 226.65K
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(180.88M) (50.78M) (55.50M) (51.11M)
Minority Interest Expense
- - - -
-
Net Income
(180.88M) (50.78M) (55.50M) (51.11M)
Net Income Growth
-90.38% +71.93% -9.30% +7.91%
Net Margin Growth
-495.94% -28.68% -22.17% -16.47%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(180.88M) (50.78M) (55.50M) (51.11M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(180.88M) (50.78M) (55.50M) (51.11M)
EPS (Basic)
-4.2572 -1.1108 -1.1353 -1.0224
EPS (Basic) Growth
-42.41% +73.91% -2.21% +9.94%
Basic Shares Outstanding
42.49M 45.71M 48.89M 49.99M
EPS (Diluted)
-4.2572 -1.1108 -1.1353 -1.0224
EPS (Diluted) Growth
-42.41% +73.91% -2.21% +9.94%
Diluted Shares Outstanding
42.49M 45.71M 48.89M 49.99M
EBITDA
(177.04M) (56.40M) (55.76M) (66.28M)
EBITDA Growth
-70.00% +68.14% +1.13% -18.87%
EBITDA Margin
-485.40% -31.86% -22.27% -21.36%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 64.296
Number of Ratings 17 Current Quarters Estimate -0.19
FY Report Date 12 / 2025 Current Year's Estimate -0.336
Last Quarter’s Earnings N/A Median PE on CY Estimate N/A
Year Ago Earnings -1.02 Next Fiscal Year Estimate -0.875
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 16 10 16 17
Mean Estimate -0.19 -0.15 -0.34 -0.87
High Estimates 0.17 0.02 -0.11 0.45
Low Estimate -0.77 -0.39 -0.88 -2.28
Coefficient of Variance -111.73 -94.02 -58.54 -80.64

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 12 12 12
OVERWEIGHT 1 1 2
HOLD 3 3 3
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Immunocore Holdings - IMCR

Date Name Shares Transaction Value
Mar 21, 2025 Baker Bros. Advisors LP Director 170,007 Open market or private purchase of non-derivative security Non-derivative transaction at $29.74 per share 5,056,008.18
Mar 21, 2025 Baker Bros. Advisors LP Director 2,051,711 Open market or private purchase of non-derivative security Non-derivative transaction at $29.74 per share 61,017,885.14
Mar 21, 2025 Baker Bros. Advisors LP Director 178,596 Open market or private purchase of non-derivative security Non-derivative transaction at $29.56 per share 5,279,297.76
Mar 21, 2025 Baker Bros. Advisors LP Director 2,144,060 Open market or private purchase of non-derivative security Non-derivative transaction at $29.56 per share 63,378,413.60
Mar 21, 2025 Baker Bros. Advisors LP Director N/A Open market or private sale of non-derivative or derivative security 0.00
Mar 21, 2025 Baker Bros. Advisors LP Director N/A Open market or private sale of non-derivative or derivative security 0.00

Immunocore Holdings in the News